Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor (α1A-AR; α1D-AR)

Molecular Classification

G protein-coupled receptor, Receptor

Other Names

ADRA1A, ADRA1D, α1A-adrenoceptor, α1D-adrenoceptor, alpha-1A adrenoceptor, alpha-1D adrenoceptor

Disease Roles

Cardiovascular disease (including hypertension)Lower urinary tract symptoms (benign prostatic hyperplasia)Neurological disorders (via cognitive function modulation)

Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor Overview

The alpha-1A and alpha-1D adrenergic receptors are subtypes of the alpha-1 adrenergic receptor family, which are G protein-coupled receptors primarily responsive to the endogenous catecholamines noradrenaline and adrenaline[1][2][3][4]. These receptors play essential roles in regulating vascular smooth muscle contraction, controlling blood pressure, modulating lower urinary tract function, and influencing cognition[2][3][4]. There are three α1-adrenoceptor subtypes: α1A, α1B, and α1D, each with overlapping but distinct tissue distributions and functional roles. The α1A subtype is particularly important in the prostate and lower urinary tract, while both α1A and α1D are expressed in vascular tissues and involved in blood pressure regulation[1][3]. They are major targets for antihypertensive and urological therapies, especially selective antagonists for the treatment of hypertension and benign prostatic hyperplasia. Selective drugs targeting these subtypes are being developed to maximize clinical benefits and reduce unwanted side effects driven by less selective inhibition of related receptor subtypes[2][3][5].

Mechanism of Action

Agonists stimulate Gq protein signaling, activating phospholipase C (PLC), leading to inositol trisphosphate (IP3) and diacylglycerol (DAG) formation, triggering intracellular calcium release and kinase activation. Antagonists block these signaling pathways, reducing smooth muscle contraction and lowering vascular/urinary tract tone.

Biological Functions

Signal transduction

Smooth muscle contraction

Regulation of blood pressure

Cognitive function

Regulation of cell growth and proliferation

Disease Associations

Cardiovascular disease (including hypertension)

Lower urinary tract symptoms (benign prostatic hyperplasia)

Neurological disorders (via cognitive function modulation)

Other potential roles in cancer, metabolic, and inflammatory disorders

Safety Considerations

Orthostatic hypotension (with antagonists)
Reflex tachycardia
Dizziness
Sexual dysfunction (including ejaculatory disorders)
Selectivity is important to minimize off-target effects (e.g., on α1B-ARs, which can affect cardiac function)

Interacting Drugs

Tamsulosin (antagonist, clinically used for BPH)

Oxymetazoline (selective agonist for α1A-AR)

A61603 (synthetic selective agonist for α1A-AR)

Cyclazosin (antagonist)

BMY 7378 (antagonist, α1D and α2C selectivity)

Domesticine (antagonist)

Prazosin, doxazosin, terazosin (antagonists, less subtype-selective, clinical hypertension/BPH use)

Noradrenaline/epinephrine (endogenous agonists)

Associated Biomarkers

Biomarker
There are no well-established protein biomarkers for patient selection; functional readouts (e.g., blood pressure response, urodynamic studies) are used clinically.